Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL
This is the first trial to show that a MRD-guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of PFS and OS.
United Kingdom United States American Society Of Hematology University Of Leeds International Workshop On Chronic Lymphocytic Leukemia Peter Hillmen
Source: pharmacytimes.com